The total return over the past 12 months is +14.18% vs. +16.94% for the S&P 500. So far it's up -9.06% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +14.18% | +58.99% | +28.33% | N/A | N/A | N/A |
| Total Return CAGR | +14.18% | +58.99% | +28.33% | N/A | N/A | N/A |
| Revenue CAGR | +105.17% | +264.59% | +61.36% | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Tarsus Pharmaceuticals, Inc. (TARS)
| Year | Start price | End price | TARS Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $81.88 | $74.46 | (9.06%) | +14.51% | (23.57%) |
| 2025 | $55.37 | $81.88 | +47.88% | +17.72% | +30.16% |
| 2024 | $20.25 | $55.37 | +173.43% | +24.89% | +148.54% |
| 2023 | $14.66 | $20.25 | +38.13% | +26.19% | +11.94% |
| 2022 | $22.50 | $14.66 | (34.84%) | (18.17%) | (16.67%) |
| 2021 | $41.33 | $22.50 | (45.56%) | +28.74% | (74.30%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
